At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MDGL Madrigal Pharmaceuticals
Pre-Mkt 02-19 09:07:45 EST
491.49
+4.17
+0.86%
盘前463.00
-28.49-5.80%
09:06 EST
High498.10Low480.00Vol316.82K
Open486.71D1 Closing487.32Amplitude3.71%
Mkt Cap11.16BTradable Cap5.41BTotal Shares22.71M
T/O155.35MT/O Rate2.88%Tradable Shares11.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Stock Track | Madrigal Pharmaceuticals Plunges 6.41% in Pre-Market After Q4 Earnings Miss
Stock Track  ·  20:24
Stock Track | Madrigal Pharmaceuticals Plunges 6.41% in Pre-Market After Q4 Earnings Miss
Earnings Flash (MDGL) Madrigal Pharmaceuticals Posts Q4 Net Loss $2.57 a Share, vs. FactSet Est of $0.90 Loss
MT Newswires Live  ·  20:12
Earnings Flash (MDGL) Madrigal Pharmaceuticals Posts Q4 Net Loss $2.57 a Share, vs. FactSet Est of $0.90 Loss
Madrigal posts FY 2025 net revenues of USD 958.4 million
Reuters  ·  20:04
Madrigal posts FY 2025 net revenues of USD 958.4 million
Madrigal Pharmaceuticals Q4 2025 EPS $(2.57) Misses $(0.40) Estimate, Sales $321.083M Beat $312.490M Estimate
Benzinga  ·  20:02
Madrigal Pharmaceuticals Q4 2025 EPS $(2.57) Misses $(0.40) Estimate, Sales $321.083M Beat $312.490M Estimate
BRIEF-Madrigal Pharmaceuticals Q4 EPS USD -2.57
Reuters  ·  20:00
BRIEF-Madrigal Pharmaceuticals Q4 EPS USD -2.57
Madrigal Pharmaceuticals Q4 Product Revenue USD 321.083 Million
THOMSON REUTERS  ·  20:00
Madrigal Pharmaceuticals Q4 Product Revenue USD 321.083 Million
Madrigal Pharmaceuticals Q4 Net Income USD -58.575 Million
THOMSON REUTERS  ·  20:00
Madrigal Pharmaceuticals Q4 Net Income USD -58.575 Million
Madrigal Pharmaceuticals Q4 Operating Income USD -59.609 Million
THOMSON REUTERS  ·  20:00
Madrigal Pharmaceuticals Q4 Operating Income USD -59.609 Million
Madrigal Pharmaceuticals Q4 Operating Expenses USD 380.692 Million
THOMSON REUTERS  ·  20:00
Madrigal Pharmaceuticals Q4 Operating Expenses USD 380.692 Million
Madrigal Pharmaceuticals Grants Equity Awards to New Employees
Reuters  ·  02-18 05:05
Madrigal Pharmaceuticals Grants Equity Awards to New Employees
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Madrigal Pharmaceuticals (MDGL), Doximity (DOCS) and Humana (HUM)
TIPRANKS  ·  02-12
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Madrigal Pharmaceuticals (MDGL), Doximity (DOCS) and Humana (HUM)
Earning Preview: Madrigal Pharmaceuticals revenue is expected to increase by 217.06%, and institutional views are predominantly bullish
Earnings Agent  ·  02-12
Earning Preview: Madrigal Pharmaceuticals revenue is expected to increase by 217.06%, and institutional views are predominantly bullish
Ribo and Ribocure Announce Exclusive Global Licensing Agreement With Madrigal for Novel Sirna Therapeutics Targeting Mash
THOMSON REUTERS  ·  02-11
Ribo and Ribocure Announce Exclusive Global Licensing Agreement With Madrigal for Novel Sirna Therapeutics Targeting Mash
BRIEF-Madrigal Expands Its Mash Pipeline With Exclusive Global Licensing Agreement For Six Preclinical Sirna Programs
Reuters  ·  02-11
BRIEF-Madrigal Expands Its Mash Pipeline With Exclusive Global Licensing Agreement For Six Preclinical Sirna Programs
Madrigal, Suzhou Ribo in license deal for liver‑disease programs
Reuters  ·  02-11
Madrigal, Suzhou Ribo in license deal for liver‑disease programs
Madrigal Pharmaceuticals announces exclusive license pact with Suzho Ribo
TIPRANKS  ·  02-11
Madrigal Pharmaceuticals announces exclusive license pact with Suzho Ribo
BRIEF-Suzhou Ribo Life Science Signs Exclusive Worldwide Licensing Deal With Madrigal
Reuters  ·  02-11
BRIEF-Suzhou Ribo Life Science Signs Exclusive Worldwide Licensing Deal With Madrigal
Madrigal Pharmaceuticals Licenses Six siRNA Programs from Ribo Life Science
Reuters  ·  02-11
Madrigal Pharmaceuticals Licenses Six siRNA Programs from Ribo Life Science
Suzhou Ribo Life Science - Licensing Deal for 6 Pre-Clinical Sirna Programs for Treatment of Metabolic Dysfunction-Associated Steatohepatitis
THOMSON REUTERS  ·  02-11
Suzhou Ribo Life Science - Licensing Deal for 6 Pre-Clinical Sirna Programs for Treatment of Metabolic Dysfunction-Associated Steatohepatitis
Madrigal Pharmaceuticals Inc - Announces Exclusive Global License Agreement With Suzhou Ribo
THOMSON REUTERS  ·  02-11
Madrigal Pharmaceuticals Inc - Announces Exclusive Global License Agreement With Suzhou Ribo

Introduction

Company Name.
Madrigal Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.
Issue price:
--